MAIA Biotechnology
Market cap $77.2M 61.8M shares (10-Q, Nov 9, 2026) × $1.25 close Nov 17, 2026
Most recent annual filing: 2026-03-23
- THIO-101 expansion cohort filing2026THIO-101 expansion cohort filing, 2026, material
- THIO-102 trial start2026THIO-102 trial start, 2026, notable
- THIO-101 Parts C/D corporate update2026THIO-101 Parts C/D corporate update, 2026, notable
- THIO-104 Phase 3 Ph3 interim2027THIO-104 Phase 3 Ph3 interim, 2027, material
- Wainwright litigation rulingFeb 11, 2027Wainwright litigation ruling, Feb 11, 2027, routine
- THIO-104 Ph3 interimmid-2027THIO-104 Ph3 interim, mid-2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
ateganosine
THIO · 6-thio-dG · 6-thio-2'-deoxyguanosineMAIA-2021-20
- Undisclosed indication
MAIA-2022-12
- Undisclosed indication
MAIA-2021-029
- Undisclosed indication
ateganosine
THIOCapital (as filed)
- Cash
- $0K cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$6.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $21.3M cash, runway mid-2027 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Offering documents (5)
- 2026-10-07 424B3 · Resale (selling stockholders)
- 2026-10-02 424B3 · Resale (selling stockholders)
- 2026-09-25 S-3 · Shelf registration
- 2026-08-21 S-3 · Shelf registration up to $150M aggregate
- 2026-05-14 424B5 · At-the-market program up to $11.2M
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (12)
- 2026-11-18 UPDATE: MAIA Biotechnology (MAIA) - Another DCR, Still No ORR 🔒 Paid
- 2026-11-10 UPDATE: MAIA Biotechnology (MAIA) - The Going-Concern Math Arrives 🔒 Paid
- 2026-10-08 UPDATE: MAIA Biotechnology (MAIA) - Part C Is Closed, the Phase 3 Hits 65 🔒 Paid
- 2026-08-11 UPDATE: MAIA Biotechnology (MAIA) - The Burn Rate Catches Up 🔒 Paid
- 2026-07-08 UPDATE: MAIA Biotechnology (MAIA) - Part C Delivers a 90.5% Disease Control Rate 🔒 Paid
- 2026-06-25 UPDATE: MAIA Biotechnology (MAIA) - International Part C Enrollment Is Done 🔒 Paid
- 2026-06-04 UPDATE: MAIA Biotechnology (MAIA) - The Phase 3 Number, and the Interim Slips to 2027 🔒 Paid
- 2026-06-03 UPDATE: MAIA Biotechnology (MAIA) - The U.S. Door Opens for the Accelerated Approval Cohort 🔒 Paid
- 2026-06-02 UPDATE: MAIA Biotechnology (MAIA) - The CEO Doubles Down, and a Director Joins Him 🔒 Paid
- 2026-05-15 UPDATE: MAIA Biotechnology (MAIA) - The Wainwright Divorce Is Final 🔒 Paid
- 2026-05-12 UPDATE: MAIA Biotechnology (MAIA) - The Banker Lawsuit Lands and a Bitcoin Plan Surfaces
- 2026-03-30 Maia Biotechnology (MAIA) - Scientific Deep Dive for Ateganosine and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (12 calls)
Every verdict Biotech Distilled has published on MAIA Biotechnology, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-03-30 Speculative buy speculative Maia Biotechnology (MAIA) - Scientific Deep Dive for Ateganosine and Pipeline Products The mechanism is chemically elegant and Phase 2 survival data is compelling, but near-term dilution and method-of-use patent risks require a speculative position sizing.
- 2026-05-12 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Banker Lawsuit Lands and a Bitcoin Plan Surfaces Clinical thesis intact with dilution gap closed and lawsuit quantified, but a new governance concern — a board-authorized plan to put up to 90% of treasury into crypto — warrants heightened scrutiny.
- 2026-05-15 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Wainwright Divorce Is Final ATM termination removes a dilution lever and is a governance cleanup, but the crypto treasury plan and Tranche 2 financing structure remain unresolved; clinical thesis unchanged.
- 2026-06-02 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The CEO Doubles Down, and a Director Joins Him CEO and director open-market buys are incrementally bullish but governance rakes remain; insider signal is worth noting, not yet worth re-rating.
- 2026-06-03 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The U.S. Door Opens for the Accelerated Approval Cohort FDA clearance of the IND amendment enabling U.S. enrollment in the Accelerated Approval cohort is an incremental operational de-risk, but governance overhang is unchanged.
- 2026-06-04 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Phase 3 Number, and the Interim Slips to 2027 First hard Phase 3 enrollment number is encouraging but the interim analysis has formally slipped to 2027, extending the holding period; Parts C/D ORR is now the closer catalyst.
- 2026-06-25 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - International Part C Enrollment Is Done International Part C enrollment closed with U.S. sites ramping; ORR readout is the next clinically relevant data point, but governance overhang is unchanged.
- 2026-07-08 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - Part C Delivers a 90.5% Disease Control Rate 90.5% DCR in Part C tracks Parts A/B in a harder-to-treat population, retiring the small-N reversion bear case; ORR remains the next key number for Accelerated Approval.
- 2026-08-11 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Burn Rate Catches Up Clinical thesis intact but burn rate stepped up to ~$6.8M/quarter, thinning the runway and bringing a financing conversation into view for 2027; crypto plan still not rescinded.
- 2026-10-08 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - Part C Is Closed, the Phase 3 Hits 65 Part C enrollment complete and THIO-104 at 65 patients, but a $1M stock-for-trial-funding deal signals the 'fully funded' framing has worn thin and ORR is still missing.
- 2026-11-10 Hold UPDATE: MAIA Biotechnology (MAIA) - The Going-Concern Math Arrives Runway has shrunk to ~3.4 quarters, going-concern language now rests on R&D cost cuts during a pivotal trial, and the next financing looks likely to arrive before the next data catalyst.
- 2026-11-18 Hold UPDATE: MAIA Biotechnology (MAIA) - Another DCR, Still No ORR Pooled 88% DCR is consistent but ORR — the primary endpoint and Accelerated Approval anchor — is still missing; balance sheet unchanged and the 24% pop may invite a dilutive raise.
- Long call · opened Mar 30, 2026 at $1.31 · -4.6% vs XBI +22.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (43)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Mar 31, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseMAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer→ BD update
- Nov 17, 20268-KCurrent report: Reg FD disclosure · EX-99.1→ BD update
- Nov 9, 202610-QQuarterly report→ BD updateThe Q3 10-Q lands with $21.3M cash, a burn rate that's converging on the same ~$6M quarterly pace as Q2, the Digital Asset Treasury Plan still "on hold" for a third straight quarter, and the Wainwright hearing now pushed to February 2027. The science is unchanged — but the financial runway math just got tighter.
- Oct 7, 2026ReleaseMAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer→ BD updateSummary on the 424B3BD extracted 1 program update from this document → MAIA pipeline
- Oct 7, 2026424B3Prospectus (resale / update)→ BD updateMAIA closes Part C enrollment and prints a 65-patient Phase 3 count — the two enrollment watch items from the August update in one release — while a quiet Clinical Trial Funding Agreement with PoC Capital surfaces a new $1M non-dilutive (ish) financing structure the tape hasn't fully priced.
- Oct 6, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Oct 2, 2026424B3Prospectus (resale / update)
- Sep 25, 2026S-3Shelf registration
- Sep 23, 2026ReleaseMAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
- Sep 22, 2026ReleaseMAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung CancerBD extracted 1 program update from this document → MAIA pipeline
- Sep 16, 2026ReleaseMAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
- Sep 15, 2026ReleaseMAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
- Sep 10, 2026ReleaseMAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
- Aug 21, 2026S-3Shelf registration
- Aug 10, 202610-QQuarterly report
- Jul 8, 2026ReleaseMAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion TrialBD extracted 1 program update from this document → MAIA pipeline
- Jun 25, 2026ReleaseMAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
- Jun 18, 2026ReleaseMAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
- Jun 10, 2026ReleaseMAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
- Jun 4, 2026ReleaseMAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
- Jun 3, 2026ReleaseMAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial ExpansionBD extracted 2 program updates from this document → MAIA pipeline
- Jun 2, 2026ReleaseMAIA Biotechnology Announces Open Market Purchases by CEO and Director
- Jun 1, 2026ReleaseMAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical OncologyBD extracted 1 program update from this document → MAIA pipeline
- May 22, 20268-KCurrent report: shareholder vote
- May 19, 2026DEFA14AProxy soliciting material
- May 14, 20268-KCurrent report: agreement terminated
- May 14, 2026424B5Prospectus supplement (offering)
- May 11, 202610-QQuarterly report
- Apr 27, 2026DEFA14AProxy soliciting material
- Apr 16, 2026ReleaseMAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
- Apr 16, 20268-KCurrent report: other events · EX-99.1
- Apr 8, 2026ReleaseMAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
- Apr 8, 20268-KCurrent report: other events · EX-99.1
- Apr 7, 2026DEFA14AProxy soliciting material
- Apr 7, 2026DEF 14AProxy statement
- Apr 2, 20268-KCurrent report: officer / director change
- Mar 31, 2026ReleaseMAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
- Mar 31, 20268-KCurrent report: other events · EX-99.1
- Mar 27, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Mar 23, 202610-KAnnual report
- Mar 4, 20268-KCurrent report: material agreement, other events · EX-99.1
- Mar 4, 2026424B5Prospectus supplement (offering)
- Mar 2, 2026424B5Prospectus supplement (offering)
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Oct 6, 2026EFFECTRegistration effective
- Aug 28, 2026EFFECTRegistration effective
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 7, 2026S-8Employee plan registration
- Apr 7, 2026ARSAnnual report to shareholders